Does Buspirone cause sweating? (3+ risk factors)
By
Dr Natalia Marceli Stephanes (PhD)
Author bio
Dr Natália Marcéli Stephanes PhD is a Pharmacist with expertise in Drugs Administration and Toxicity; Discovery of New Drugs; Cancer Treatment; Biochemical Analyzes and Hematological Analyzes. She writes and reviews content on these topics.
Dr Natália Marcéli Stephanes’ Highlights:
- Pharmacist at the Department of Health of Santa Catarina State, Brazil
- PhD with a focus on oncology treatment
- Years of experience in commercial pharmacy
- Bachelor, Master and PhD degrees in Pharmacy at the Federal University of Santa Catarina
Professional Experience:
From her undergraduate studies to her Master’s and Doctorate degrees in Pharmacy, Dr Natália Marcéli Stephanes has participated in numerous scientific studies in the field of oncology and onco-hematology at the University Hospital of the Federal University of Santa Catarina, Brazil. Her research has focused on understanding the molecular and biochemical bases of malignant neoplasms and investigating safer and more effective therapeutic alternatives.
Dr Natália Marcéli Stephanes has also served as an assistant professor of haematology for undergraduate students at the Federal University of Santa Catarina. Additionally, she held the position of professor of Hospital Pharmacy at the Qualificar Technical School in Brazil, where she developed instructional materials for use in the Pharmacy Postgraduate Program at the Leonardo Da Vinci University Center.
In addition to her academic experiences, Dr Natália Marcéli Stephanes possesses a strong expertise in commercial pharmacy, with in-depth knowledge of medications, their routes of administration, desired effects, adverse effects, and toxicity.
Currently, Dr Natália Marcéli Stephanes works as a Pharmacist at the Health Department of Santa Catarina State, where her role entails providing pharmaceutical scientific consulting services to judges.
Education:
- 2016 Bachelor in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2018 Master in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2023 PhD in Pharmacy at the Federal University of Santa Catarina, Brazil
The main publications of Dr Natália Marcéli Stephanes are:
Falchetti M ; Delgobo M, Zancanaro H, Almeida K, Das Neves RN, Dos Santos B, Stefanes NM, et al. Bishop Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. Comput. Biol. Med [Internet]. 2023; 152:106347.
Feuser PM, Matos dos Santos PC, Cordeiro AP, Stefanes NM, Walter LO, Maioral MF, Santos-Silva MC, et al. Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). J Drug Deliv Sci Technol [Internet]. 2022; 67:102924.
Jacques AV, Stefanes NM, Walter LO, Perondi DM, Efe FL, Souza LFS, Sens L, et al. Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines. Bioorg. Chem [Internet]. 2021; 116:105315.
Duarte BF, Vieira DSC, Lisboa ML, Stefanes NM, Grando LJ, Santos-Silva MC. Características clínico-epidemiológicas de pacientes portadores de carcinoma de células escamosas de boca. Arquivos Catarinenses de Medicina. 2021; 50(2): 232–245.
Machado V, Jacques AV, Stefanes NM, Santos-Silva MC, Biavatti MW. Anti-leukemic activity of semisynthetic derivatives of Lupeol. Nat. Prod. Res. 2021; 35(22):4494-4501.
Bigolin A, Maioral MF, Stefanes NM, Mascarello A, Chiaradia-Delatorre LD, Nunes RJ, Yunes RA, et al. A novel sulfonamide derivative as a strong and selective apoptotic agent against hematological malignancies. Chem. Pap. 2020; 74:2965–2976.
Bigolin A, Maioral MF, Stefanes NM, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Anticancer Drugs. 2020; 31(7):709-717.
Maioral MF, Stefanes NM, Neufeldt PD, Chiaradia-Delatorre LD, Nunes RJ, Santos-Silva MC. Aldehyde biphenyl chalcones induce immunogenic apoptotic-like cell death and are promising new safe compounds against a wide range of hematologic cancers. Future Med. Chem. 2020; 12(8):673–688.
Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, Cury NM, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs. 2019; 30(8):p 828-837.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Argenta DF, Dotto MER, Santos-Silva MC, et al. PEO-chitosan nanofibers containing carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanoparticles loaded with pyrazoline for skin cancer treatment. Eur. Polym. J. 2019; 119:335-343.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Santos-Silva MC, Nunes RJ, Parize AL, et al. A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity. Mater. Sci. Eng. C [Internet]. 2019; 105:110051.
Maioral MF, Stefanes NM, Bigolin A, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Miconidine acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells. Invest. New Drugs. 2019; 37:912–922.
Srefanes NM, Toigo J, Maioral MF, Jacques AV, Chiaradia-Delatorre LD, Perondi DM, Ribeiro AAB, et al. Synthesis of novel pyrazoline derivatives and the evaluation of death mechanisms involved in their antileukemic activity. Bioorg. Med. Chem. 2019; 27(2):375-382.
Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochim. 2017; 140:48-57.
You can view some of Dr Natália’s work below and links to her professional profile below.
Research Gate: https://www.researchgate.net/profile/Natalia-Stephanes
Linkedin: https://www.linkedin.com/in/nataliamarceli/
In this article, we will discuss Buspirone-induced sweating. We will also discuss some factors that may put some people at a higher risk of this side, as compared to others. We will also discuss what one should do if this side effect occurs.
Does Buspirone cause sweating?
Buspirone may cause sweating in some individuals. It is listed as a rare or uncommon side effect of Buspirone and not many cases have been reported so far (1).
Buspirone is a medication used to treat anxiety, and it controls excessive sweating and palpitations associated with anxiousness (2). However, it’s important to remember that the occurrence of side effects like sweating does not mean the medication is unsafe or ineffective.
It’s a matter of how your body reacts to the medication. If your sweating persists or starts affecting the quality of your life, please reach out to your healthcare provider.
What does research suggest?
There is limited research on sweating induced by Buspirone. One research study indicated that only 1% of the people taking Buspirone have reported this side effect (3). The exact mechanism through which Buspirone may cause sweating is not fully understood.
However, research suggests that Buspirone affects certain chemicals in the brain, especially serotonin and dopamine (2). Serotonin, in particular, is involved in many bodily functions, including temperature regulation (4).
When the medication affects serotonin levels, it might result in your body feeling warmer than usual, and as a response, you might start sweating to cool down (4).
This is one of the main reasons why serotonin-specific antidepressants, like Lexapro (Escitalopram), can also cause sweating as a side effect (5). However, it is important to note that not everyone will experience this side effect while taking Buspirone.
People who do experience this usually start to get better as their bodies adjust to the medication.
What are the risk factors for Buspirone-induced sweating?
There are some risk factors for Buspirone-induced sweating. These include:
- Dosage strength – people at higher doses are at a higher risk of side effects.
- Individual response to the drug – people can react differently to medications.
- Concomitant use of other medications – Buspirone can be paired with other medications, like antidepressants, which may increase the risk of excessive sweating.
- Underlying health conditions – some people may experience increased sweating because of an underlying health condition.
- Environmental factors – people living in hot and humid weather are more likely to sweat while taking Buspirone, as compared to people living in colder weather.
Remember, sweating on Buspirone is not that common and these factors might increase the risk of getting this side effect.
What to do if Buspirone causes sweating as a side effect?
It is important to consult your doctor if Buspirone causes excessive sweating. Your doctor might consider lowering the dosage of Buspirone to see if that reduces the sweating while still effectively managing your symptoms.
Changing the timing of taking Buspirone may also help sometimes. In most cases, the side effect begins to fade away on its own as the body adjusts to the effects of Buspirone.
However, in some cases, the side effect may persist and your doctor may prescribe another medication to control sweating or safely switch you to another anti-anxiety medication. Just make sure you don’t stop taking Buspirone without your doctor’s approval.
Medications like Buspirone are tapered off and they should never be discontinued abruptly. Doing so can subject you to disturbing withdrawal symptoms. This is why always reach out to your doctor to discuss your concerns.
Conclusion
In this article, we have discussed Buspirone-induced sweating. We have also discussed the possible mechanism through which this med can trigger sweating and what one should do if this side effect occurs.
Was this helpful?
References
1.-
National Library of Medicine. Buspirone: MedlinePlus Drug Information [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://medlineplus.gov/druginfo/meds/a688005.html
2.-
Wilson TK, Tripp J. Buspirone. 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30285372. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531477
3.-
Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the side-effect profile of buspirone. Am J Med. 1986 Mar 31;80(3B):17-21. doi: 10.1016/0002-9343(86)90327-x. PMID: 2870641. Available from: https://pubmed.ncbi.nlm.nih.gov/2870641/
4.-
Kanova M, Kohout P. Serotonin-Its Synthesis and Roles in the Healthy and the Critically Ill. Int J Mol Sci. 2021 May 3;22(9):4837. doi: 10.3390/ijms22094837. PMID: 34063611; PMCID: PMC8124334. Available from: https://pubmed.ncbi.nlm.nih.gov/34063611/
5.-
Marcy TR, Britton ML. Antidepressant-induced sweating. Ann Pharmacother. 2005 Apr;39(4):748-52. doi: 10.1345/aph.1E564. Epub 2005 Feb 22. PMID: 15728327. Available from: https://pubmed.ncbi.nlm.nih.gov/15728327/
